190 related articles for article (PubMed ID: 2477559)
1. Clinical use of prostate specific antigen in patients with prostate cancer.
Hudson MA; Bahnson RR; Catalona WJ
J Urol; 1989 Oct; 142(4):1011-7. PubMed ID: 2477559
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
3. The value of serum prostate specific antigen determinations before and after radical prostatectomy.
Lange PH; Ercole CJ; Lightner DJ; Fraley EE; Vessella R
J Urol; 1989 Apr; 141(4):873-9. PubMed ID: 2467013
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC
J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037
[TBL] [Abstract][Full Text] [Related]
5. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.
Ercole CJ; Lange PH; Mathisen M; Chiou RK; Reddy PK; Vessella RL
J Urol; 1987 Nov; 138(5):1181-4. PubMed ID: 2444720
[TBL] [Abstract][Full Text] [Related]
6. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Carter HB; Partin AW; Epstein JI; Chan DW; Walsh PC
J Urol; 1990 Nov; 144(5):1167-70; discussion 1170-1. PubMed ID: 1700143
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
9. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
11. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
Iwakiri J; Granbois K; Wehner N; Graves HC; Stamey T
J Urol; 1993 Apr; 149(4):783-6. PubMed ID: 7681118
[TBL] [Abstract][Full Text] [Related]
12. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
13. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
14. Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer.
Bigg SW; Kavoussi LR; Catalona WJ
J Urol; 1990 Dec; 144(6):1420-4. PubMed ID: 1700156
[TBL] [Abstract][Full Text] [Related]
15. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
18. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
[TBL] [Abstract][Full Text] [Related]
19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
20. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks.
Tewari A; Narayan P
J Urol; 1998 Aug; 160(2):430-6. PubMed ID: 9679892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]